Soaring Demand Set to Propel Antimicrobial Susceptibility Testing Market to $5.76 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Antimicrobial Susceptibility Testing Market Through 2025?
The overall scope of the antimicrobial susceptibility testing sector has experienced considerable expansion lately, projected to escalate from a valuation of $4.36 billion in 2024 to $4.65 billion by 2025, reflecting a consistent annual growth rate approximating 6.8%; this upward trajectory over the past period stems from several key factors including increasing spending on healthcare services, a growing demographic of older individuals, heightened public knowledge and educational initiatives, favorable governmental guidelines, and broader economic development.

What's the Projected Size of the Global Antimicrobial Susceptibility Testing Market by 2029?
Antimicrobial susceptibility testing market is projected to experience robust expansion in the coming years, reaching a valuation of $5.76 billion by 2029, propelled by a compound annual growth rate (CAGR) of 5.5%; this upward trajectory during the projection span is fueled by the escalating incidence of infections resistant to drugs, enhancements in healthcare facilities, heightened focus on discovering new medications, and an increase in personal disposable income.Key developments anticipated to shape this market in the forecast timeframe encompass the adoption of automation and robotics, the integration of artificial intelligence and machine learning, the utilization of multiplexing techniques, the connection with telemedicine platforms, and the advancement of quicker AST methodologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/antimicrobial-susceptibility-testing-global-market-report

Top Growth Drivers in the Antimicrobial Susceptibility Testing Industry: What's Accelerating the Market?
An escalation in worldwide infectious disease occurrences has fueled the expansion of the antimicrobial susceptibility testing market; these maladies stem from various agents such as bacteria, viruses, fungi, and parasites, encompassing conditions like bacterial pneumonia and tuberculosis (caused by bacteria) or smallpox and AIDS (viral in origin). For evidence of this trend, the US national public health body, the Centers for Disease Control and Prevention, reported in March 2024 that concerning the 9,573 tuberculosis cases documented in 2023 where the country of birth was known, a significant 7,259, or 76 percent, afflicted individuals born outside the US, marking an 18 percent jump from the 6,177 comparable cases noted in 2022, which intrinsically illustrates how increasing infectious disease rates propel the expansion of the antimicrobial susceptibility testing sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4026&type=smp

What Trends Will Shape the Antimicrobial Susceptibility Testing Market Through 2029 and Beyond?
A significant development characterizing the antimicrobial susceptibility testing sector involves the growing adoption of swift testing methods aimed at preventing the inappropriate use of antibiotics while ensuring patients receive efficacious therapies. Various methodologies now allow for antimicrobial susceptibility assessments to be completed within a matter of minutes or several hours. Among these, Fluorescence in situ hybridization, or FISH, is frequently employed for rapid susceptibility determination. Specifically, the PNA-FISH technique utilizes peptide nucleic acid probes facilitating fast and precise molecular binding, a principle incorporated into QuickFish technology developed by OpGen, which identifies microorganisms by zeroing in on 16s RNA. Furthermore, as an illustration, Genefluidics Inc's system for antimicrobial susceptibility testing gauges bacterial proliferation through the measurement of 16s rRNA molecules detected via an electrochemical biosensor.

What Are the Main Segments in the Antimicrobial Susceptibility Testing Market?
The antimicrobial susceptibility testingmarket covered in this report is segmented -

1) By Type: Antibacterial Testing; Antifungal Testing; Antiparasitic Testing; Other Types
2) By Products: Manual Antimicrobial Susceptibility Testing Products; Automated Laboratory Instruments; Consumables
3) By Application: Diagnostics; Drug Discovery and Development; Epidemiology; Other Applications
4) By End User: Hospitals And Diagnostic Centers; Pharmaceutical And Biotechnology Companies; Research And Academic Institutes; Clinical Research Organizations (CROs)

Subsegments:
1) By Antibacterial Testing: Disk Diffusion Method; Broth Dilution Method; E-Test Method; Automated Systems
2) By Antifungal Testing: Broth Dilution Method; Agar Disk Diffusion Method; E-Test Method; Colorimetric Methods
3) By Antiparasitic Testing: In vitro Susceptibility Testing; Microscopic Examination; Molecular Methods
4) By Other Types: Mycobacterial Susceptibility Testing; Biofilm Susceptibility Testing; Combination Antimicrobial Testing

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=4026&type=smp

Which Top Companies are Driving Growth in the Antimicrobial Susceptibility Testing Market?
Major companies operating in the antimicrobial susceptibility testing market include BioMérieux SA, Becton dic*kinson and Company, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Accelerate Diagnostics Inc., Hi-Media Laboratories, Creative Diagnostics, Merck KGaA, Roche Diagnostics Limited, Alifax Holding S.p.A., Synbiosis Ltd., Zhuhai DL Biotech Co. Ltd., Mast Group Ltd., ELITechGroup, Genefluidics Inc., Condalab, QuantaMatrix Inc., Bruker Corporation, Eurofins Scientific SE, Liofilchem s.r.l., Hardy Diagnostics, Micromax Technologies, Bioanalyse GmbH, Lab M Limited, Microbiologics Inc., Quidel Corporation, R-Biopharm AG, SSI Diagnostica A/S, VWR International LLC, ZeptoMetrix Corporation

Which Regions Will Dominate the Antimicrobial Susceptibility Testing Market Through 2029?
North America was the largest region in the antimicrobial susceptibility testing market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4026

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.